Norway: problems which a small and sparsely populated European country without a national vaccine production would face during a pandemic
- PMID: 7843374
- DOI: 10.1007/BF01719694
Norway: problems which a small and sparsely populated European country without a national vaccine production would face during a pandemic
Abstract
Since Norway at present has no national influenza vaccine production, there is some concern that during a pandemic influenza situation it would be difficult to secure even a limited quantity of appropriate influenza vaccine. It is conceivable that national emergency directives declared in the manufacturing countries would ban or severely hinder export of a life-saving commodity such as influenza vaccine. Most probably, this would be the situation for all European countries without a national influenza vaccine production. To ensure vaccine availability for the purchasing country even under a national influenza emergency situation declared in the manufacturing country such agreements must be safe against unilateral cancellation.
Similar articles
-
Populations of persons who must be vaccinated with priority.Eur J Epidemiol. 1994 Aug;10(4):511-2. doi: 10.1007/BF01719691. Eur J Epidemiol. 1994. PMID: 7843371
-
[Influenza vaccine: globalization of public health stakes].Med Trop (Mars). 2009 Aug;69(4):322. Med Trop (Mars). 2009. PMID: 19725377 French.
-
Influenza vaccine supply: building long-term sustainability.Vaccine. 2008 Sep 12;26 Suppl 4:D23-6. doi: 10.1016/j.vaccine.2008.07.067. Vaccine. 2008. PMID: 19230154 Review.
-
Pandemic influenza and the global vaccine supply.Clin Infect Dis. 2003 Jun 15;36(12):1552-61. doi: 10.1086/375056. Epub 2003 Jun 5. Clin Infect Dis. 2003. PMID: 12802755
-
Selection of influenza vaccine strains and developing pandemic vaccines.Vaccine. 2002 Dec 20;20 Suppl 5:B40-4. doi: 10.1016/s0264-410x(02)00509-1. Vaccine. 2002. PMID: 12477418 Review.
MeSH terms
Substances
LinkOut - more resources
Medical